Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 3Terminated 2

Sponsor Class

OTHER 7INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Gastrointestinal 1

Conditions

Melanoma 3Liver Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Docosahexaenoic Acids × 1 year × Clear all
NCT00244816 2025-10-23

Taxoprexin® Treatment for Advanced Eye Melanoma

American Regent, Inc.

Phase 2 Completed
22 enrolled
Dermatologic

Melanoma

NCT00422877 2025-10-16

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

American Regent, Inc.

Phase 2 Terminated
13 enrolled
Gastrointestinal

Liver Neoplasms

NCT00249262 2025-09-26

Taxoprexin Treatment for Advanced Skin Melanoma

American Regent, Inc.

Phase 2 Completed
30 enrolled
Dermatologic

Melanoma

NCT00243867 2025-08-01

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

American Regent, Inc.

Phase 3 Completed
518 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00087776 2025-07-23

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

American Regent, Inc.

Phase 3 Terminated
393 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡